This site is intended for health professionals only

Published on 7 December 2009

Share this story:
Twitter
LinkedIn

Prostate cancer drug recommended

teaser

Hot flushes in men receiving hormone therapy for prostate cancer should be treated with medroxyprogesterone, according to a report published in Online First in The Lancet Oncology.

Hormone – androgen suppression – uses gonadotrophin-releasing hormone (GnRH) analogues such as leuprorelin to block the production of male-producing sex hormones, or androgens.

While this suppresses tumour growth, it also causes the hot flushes – a common and unpleasant side-effect experienced by up to 80% of patients.

A French research team has found that although cyproterone, medroxyprogesterone and venlafaxine all reduced hot flushes, the former two were significantly more effective.

The report concludes: “Cyproterone acetate and medroxprogesterone acetate are more effective at 12 weeks for treating hot flushes in men treated with GnRH analogues for prostate cancer…however, as cyproterone is a recognised treatment in prostate cancer, and its use could interfere with hormone therapy, medroxprogesterone should be the standard treatment.”

Copyright Press Association 2009

The Lancet Oncology



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn